ArticleScientific reports2024
Time to recovery from visceral leishmaniasis and its predictors of mature visceral leishmaniasis patients admitted at Metema Hospital, Metema, Ethiopia.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis (VL) is a neglected tropical disease that mostly affects the working-class and impoverished segments of society, having a significant negative effect on the economic development of the affected nation. While anti-leishmanial medications lower mortality among VL patients, patients may still die or require more time to recover (TTR) while receiving treatment. In this regard, there are limited studies in Ethiopia. This study aims to determine the time to recovery and its associated predictors among adult VL patients at Metema Hospital. A hospital-based cross-sectional study design was employed, and the data were collected in patient's charts from September 2017 to September 2021. Data were entered and analyzed using Epi-data, STATA version 14.2, and R 3.4.0 statistical software. The Kaplan-Meier survival curve and log-rank tests were used to compare the survival time. The Cox proportional hazard model assumption and model fitness were checked and used to identify statistical association predictors in VL patients. The Cox proportional hazard (Cox-PH) model was fitted. The overall medium recovery time was 7 days (minimum 4, maximum 14 days). The variables nasal bleeding (adjusted hazard ratio/AHR: 0.44; 95% CI: 0.19-0.89), no comorbidity (AHR: 2.29; 95% CI: 1.27-4.11), relapse VL (AHR: 0.33; 95% CI: 0.15-0.75),low parasite load (AHR: 2.58; 95% CI: 1.48-4.51), and ambulatory (AHR: 3.26; 95% CI: 2.45-6.53) were significantly associated with TTR in VL patients. Patients with comorbidities, nasal bleeding, relapse VL, bedridden, and high parasite load should be treated and monitored carefully to recover quickly from their illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.